Nitrome Biosciences appoints Perry Karsen as Executive Chairman

– USA, CA –  Nitrome Biosciences, a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to target Parkinson’s disease and many other age-related and inflammation disorders, today announced the appointment of Perry Karsen, a seasoned leader with 35 years of life sciences experience, as Executive Chairman of its board of directors.

“Perry is a highly respected industry executive with significant expertise in leading and growing successful biopharmaceutical companies,” said founder, CEO and CSO, Dr. Irene Griswold-Prenner. “Perry’s strategic counsel and business acumen will be invaluable to Nitrome as we build out a wholly-owned first-in-class enzyme therapeutics platform based on our novel scientific discoveries.”

About Perry Karsen

Perry Karsen was CEO of Celgene Cellular Therapeutics, a division of Celgene Corporation, from 2013 until his retirement in 2015. Previously, Perry held the position of EVP and COO at Celgene, serving in various management positions, including as SVP and head of worldwide business development and president of the Asia/Pacific region. Perry was the president and CEO of Pearl Therapeutics, a biotechnology company subsequently acquired by Astra-Zeneca. In addition, Perry held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech, and Abbott Laboratories earlier in his career. He also was a general partner at Pequot Ventures focusing on investments in biotechnology and medical devices.

Perry Karsen added, “I am very excited to be a part of the Nitrome team and look forward to helping the company realize the vast potential for patients of its enzyme therapeutics platform. Irene’s breakthrough discovery could be the key to unraveling degeneration evidenced in many age and inflammation-related conditions. The potential for Nitrome to advance science and medicine while impacting patients is profound.”

Perry has a Bachelor of Science in biological sciences from the University of Illinois, Urbana, a Master of Arts in teaching biology from Duke University, and an MBA from the Kellogg School of Management at Northwestern University.

Perry serves on the board of directors and as chair of several private and public biotechnology companies, and on the board of The Gladstone Foundation. He is also a former member of the board of directors and the executive committee of the Biotechnology Innovation Organization.

About Nitrome Biosciences

Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases including Parkinson’s, Nitrome’s lead indication. The company also aims to expand its proprietary platform to include other diseases, such as other neurodegenerative diseases, macular degeneration, heart disease, and cancer. Nitrome has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson’s Research.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team